A ortic valve stenosis resulting from calcific thickening of a previously normal 3-cusp aortic valve or a congenitally bicuspid aortic valve is a common clinical condition in developed countries, and its prevalence is continuing to increase with aging of the population. 1,2 In the Cardiovascular Health Study, which involved 5201 men and women Ͼ65 years of age, the prevalence of aortic stenosis was 1.3% in subjects 65 to 75 years of age, 2.4% in subjects 75 to 85 years of age, and 4% in subjects Ͼ85 years of age. 3 The precise mechanisms involved in the pathophysiology of aortic stenosis and its progression are incompletely understood, but advancing age and atherosclerosis-related risk factors have been implicated in the process. 4 In fact, atherosclerotic coronary artery disease is present in nearly 50% of patients with aortic stenosis. 5 Studies of valve pathology have suggested a potential role for dyslipidemia, inflammation, and angiogenesis in the process, but pharmacological therapies using statins to reduce dyslipidemia and associated inflammatory processes have yielded inconsistent but largely negative results in terms of reducing the rate of progression of aortic stenosis. 6 -10 Thus, in the absence of specific and effective disease-modifying medical therapies, surgical aortic valve replacement has been and continues to be the cornerstone of management of severe aortic stenosis. There is general agreement among physicians and surgeons that when severe aortic stenosis is accompanied by 1 or more symptoms, such as chest pain, syncope or near syncope, resuscitated sudden death, shortness of breath, fatigue, effort intolerance, or left ventricular (LV) dysfunction, aortic valve replacement is recommended because of well-established dismal outcome (Ϸ50% mortality within 3 years) in unoperated symptomatic cases and overall excellent surgical outcomes with relatively low perioperative mortality and morbidity even among octogenarians [11] [12] [13] [14] [15] (Figures 1 and 2) . Thus, despite the absence of data from a randomized clinical trial, symptomatic severe aortic stenosis is considered a class 1 indication for surgery by various professional organizations. 16, 17 In some, particularly elderly patients, timely surgical aortic valve replacement is not considered because symptoms are mistakenly attributed to comorbid conditions, or the severity of underlying aortic stenosis is underestimated by traditional indices such as aortic valve gradient and peak velocity; this is particularly the case in patients with lowflow, low-gradient with depressed LV ejection fraction but is also true with a recently recognized variant associated with paradoxical low-flow, low-gradient severe aortic stenosis despite normal LV ejection fraction. 18 -20 Response by Carabello on p 125
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In the past few years, less invasive nonsurgical transcutaneous transfemoral (and to a lesser extent, transapical) techniques (such as transcatheter aortic valve implantation) for implanting a new bioprosthetic aortic valve inside a diseased
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severely stenotic native aortic valve have been developed and tested, with encouraging early results in symptomatic patients considered nonsurgical candidates or at high surgical risk. 21, 22 Thus, in the absence of life-limiting frailty and comorbidity, surgical valve replacement, or in selected cases, nonsurgical transcutaneous bioprosthetic valve implantation, is recommended for symptomatic patients with severe aortic stenosis.
The Case of Asymptomatic Severe Aortic Stenosis
Several observational studies have shown that a large number of patients with severe aortic stenosis deny symptoms for many years, consistent with the well-known presymptomatic phase that had originally been defined by Ross and Braunwald more than 40 years ago. 11 Admittedly, a certain proportion of the so-called asymptomatic subjects may have subconsciously re- 
Natural History of Asymptomatic Severe Aortic Stenosis and Results of Prophylactic Surgery
The 2 major concerns in patients with asymptomatic severe aortic stenosis are the risks of sudden death and the development of symptomatic or subclinical LV dysfunction. The overall incidence of sudden unexpected death in asymptomatic subjects with severe aortic stenosis is Ϸ0% to 4.1% per year, with approximately an average 1% annual risk. 5, 14, 23 The overall risk of sudden death in asymptomatic patients is comparable to or lower than that of surgical mortality. However, within the asymptomatic cohort, progression of the disease and development of symptoms is quite common, with variable rates of symptom development depending on the initial severity of aortic stenosis (Tables 1 and 2 ). 24 -26 Among patients Ͻ70 years of age, the overall surgical mortality associated with isolated aortic valve replacement is Ϸ1% to 3% (increasing to Ϸ5%-7% when associated coronary artery disease requires additional intervention), and it is 5% to 15% among older adults, including octogenarians and some nonagenarians. 31 In addition to death, stroke rates of 1.4% to 4.8% have been reported after aortic valve surgery. 32, 33 Thus, for the vast majority of asymptomatic patients with severe aortic stenosis, preemptive surgery would be associated with a higher risk of overall death than the natural history of the condition. In addition to surgical mortality, an aortic valve prosthesis, whether biological or mechanical, carries additional risks related to valve degeneration/failure, increased risk of endocarditis, and complications resulting from antithrombotic therapy. Thus, for the vast majority of truly asymptomatic patients with severe aortic stenosis, watchful waiting and periodic reassessment would appear to be a reasonable approach. It is important, however, to emphasize that when patients are followed up in this manner, cardiac surgery should be promptly undertaken when symptoms develop or evidence of LV dysfunction appears with a minimum of delay, because symptomatic patients do incur an increased risk of death (Ϸ2% per month). In the elderly patient with severe aortic stenosis, systemic hypertension and reduced aortic wall compliance are common comorbidities that can add additional afterload to the ventricle beyond that produced by valvular stenosis, and careful and judicious use of antihypertensive drug therapy to maintain optimal blood pressure control may be helpful in preserving LV function.
Are There Subsets of Patients With Seemingly Asymptomatic Severe Aortic Stenosis Who Are at High Risk for Cardiovascular Events?
As discussed above, a certain proportion of so-called asymptomatic subjects may have subconsciously reduced their level of activity to low levels, thereby masking their true exercise intolerance, and their exercise intolerance may be unmasked when evaluated objectively with a modified stress test performed under supervision (Table 3) .
Role of Treadmill Exercise Testing
Until a few years ago, severe aortic stenosis was considered a contraindication for provocative testing because of the potential for precipitating severe complications. Several small studies over the past decade have examined the potential role of carefully monitored treadmill exercise testing in predicting outcome in seemingly asymptomatic patients with severe aortic stenosis. 27,29,30,34 -37 These studies have indicated that a carefully supervised modified Bruce protocol can be safely applied to such patients and that induction of symptoms, ischemic manifestations, serious ventricular arrhythmias, or lack of expected rise in blood pressure and an actual hypotensive response predict an adverse outcome. 27,29,30,34 -37 These observational studies have shown that Ϸ30% of seemingly asymptomatic patients with severe aortic stenosis have an abnormal exercise test, 27 and 
Electrocardiographic Criteria for LV Hypertrophy and Strain
Recently, investigators have analyzed electrocardiographic data from 1533 asymptomatic aortic stenosis patients followed up for 4.3 years from the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial, in which patients with aortic stenosis were randomized to treatment with placebo or a combination of simvastatin and ezetimibe. 38 Electrocardiographic criteria for LV hypertrophy and LV strain pattern were related to a poor prognosis in asymptomatic aortic stenosis patients independent of clinical and echocardiographic covariates, which confirms previously reported findings. 39 These observations are intriguing and suggest that patients with asymptomatic severe aortic stenosis with these electrocardiographic findings may merit closer and more frequent follow-up.
Role of Biomarkers
Aortic stenosis increases myocardial diastolic and systolic wall stress, which induces the expression of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide, and thus, increased levels of these biomarkers are found in relationship to severity of aortic stenosis, with good correlation with the aortic valve area and severity of symptoms. 40 -42 In several studies, 
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patients with asymptomatic severe aortic stenosis and elevated natriuretic peptide levels (and those with increasing levels on serial follow-up) developed symptoms earlier and more often than patients with normal or lower natriuretic peptide levels 40 -42 (Table 4 ). These findings suggest that patients with asymptomatic severe aortic stenosis with elevated or serially rising natriuretic peptide levels should be monitored more closely for symptom development or deterioration of LV function, at which point prompt surgical intervention may need to be considered. 42 However, the precise cut points at which intervention should be considered remain to be defined.
Role of Doppler Echocardiography Predictors of Adverse Outcome in Asymptomatic Subjects With Severe Aortic Stenosis
Several observational studies have suggested that a number of parameters that can be obtained from 2-dimensional Doppler echocardiography studies during initial or sequential evaluation may portend a particularly adverse prognosis even in asymptomatic subjects (Table 3) . These parameters include evidence of very severe aortic stenosis, with an aortic valve area Ͻ0.6 cm/m 2 ; high peak aortic jet velocity of Ͼ4.5 to 5 m/s [43] [44] [45] ; rapid increase in gradient and velocity (Ͼ0.3 m/s per year); extensive valvular calcification 28 ; inappropriately increased LV mass 46 ; abnormal valvuloarterial load/impedance, also expressed as Zva (ratio of estimated LV pressure and stroke volume index) 47, 48 ; reduced LV ejection fraction (Ͻ50%); and reduced longitudinal LV strain despite normal LV ejection fraction. 49 In particular, the presence of very severe aortic stenosis with a peak aortic jet velocity exceeding 5 m/s and especially exceeding 5.5 m/s (regardless of aortic valve area) in asymptomatic subjects has been associated with a particularly poor event-free survival, ranging from 49% to 81% at 1 year, 32% to 48% at 2 years, 15% to 37% at 3 years, and 7% to 21% at 4 years. 43 It has been suggested that the presence of any 1 or more of these variables should lead to serious consideration of preemptive surgery.
Should Prophylactic Surgery Be Considered for the Subset of Patients With Asymptomatic Severe Aortic Stenosis Who Have 1 or More Features of High Risk?
As of now, there are no randomized clinical trials addressing the issue of preemptive surgery in high-risk subsets of patients with asymptomatic severe aortic stenosis; however, observational data provide some interesting insights. Kang et al 44 reported the results of surgery versus no surgery in a nonrandomized cohort of 197 asymptomatic patients with very severe aortic stenosis and normal LV ejection fraction (aortic valve area Ͻ0.75 cm 2 and peak aortic jet velocity Ͼ4.5 m/s), 102 of whom underwent preemptive surgery and 95 of whom were followed up without surgery. During an average follow-up of Ϸ50 months, the operated group had no operative deaths, no cardiac deaths, and only 3 noncardiac deaths, whereas the conventionally treated group had 18 cardiac and 10 noncardiac deaths. The estimated actuarial 6-year cardiac and all-cause mortality rates were 0% and 2% in the operated group versus 24% and 32%, respectively, in the conventionally managed group (PϽ0.001). 44 From the total group, in 57 propensity score-matched pairs, all-cause mortality was significantly lower in the operated group than in the unoperated group, with a hazard ratio of 0.135 (Pϭ0.008). 44 It has been argued that asymptomatic patients with very severe aortic stenosis or those who exhibit 1 or more other features of high risk (Table 3) should be considered for preemptive surgery to avoid the otherwise high mortality and morbidity. [43] [44] [45] 50 However, the evidence base for these recommendations is meager, with small numbers of patients and with a high likelihood of selection bias despite propensity matching, as well as the inclusion of patients who refused surgery when symptoms developed, which contributes to the high mortality in unoperated patients, and the frequent occurrence of noncardiac deaths in nonoperated patients that could not have been prevented by surgery anyway. 51 Thus, the recommendations for preemptive surgery are not entirely based on solid ground, and further evaluation, preferably with randomized trials, is needed to resolve this continuing clinical conundrum. What is a clinician to do? In the absence of clinical trial data, the clinician must monitor high-risk asymptomatic patients at closer intervals (perhaps every 3 months instead of every year as currently recommended by national guidelines) and intervene promptly, without delay, soon after the onset of symptoms or evidence of deterioration of LV function, to catch the patient before adverse events occur. A reasonable alternative to this approach might be to consider preemptive surgery for high-risk patients, provided that the expected institutional and surgeon-specific surgical mortality rates are low and especially if delays in surgery after symptom onset are likely because of a waiting list. Recently, Gada et al 52 reported results from a decisionanalytic model that accounted for not only mortality but also nonfatal adverse effects from aortic valve surgery, as well as costs associated with each surgery. The authors made certain assumptions to execute this model and compared immediate surgery to watchful waiting in asymptomatic severe aortic stenosis patients. 52 The authors concluded that watchful waiting was a better strategy for most asymptomatic patients with severe aortic stenosis, and preemptive surgery was only a better strategy if the expected sudden death rate, in the absence of surgery, would be 13% or higher. However, it is difficult to extrapolate from these model-derived data to the real-life scenario because of various assumptions involved and the lack of accounting for various comorbidities that are common in elderly patients with severe aortic stenosis that can influence outcome.
Percutaneous Transfemoral Implantation of a Bioprosthetic Aortic Valve for Severe Aortic Stenosis: Will That Change the Prevailing Strategy?
Over the past several years, transfemoral transcutaneous aortic valve implants have been used in several thousand patients with severe aortic stenosis, and 2 randomized controlled trials have been completed. 21, 22 These studies included symptomatic patients with severe aortic stenosis who were deemed either inoperable 21 or high surgical risks, 22 mostly because of comorbidity. Overall, short-term and intermediate-term follow-up has provided gratifying results with this less invasive intervention, but vascular complication rates and stroke rates are significant enough to give one pause. The short-and long-term risks and benefits of transcatheter aortic valve implantation in asymptomatic patients with severe aortic stenosis remain largely unknown. Therefore, at this time, it does not appear that such a strategy will be optimal for asymptomatic high-risk patients with aortic stenosis, but that could change in the future with improvements in technology that could result in reduced rates of stroke and vascular complications. If and when that happens, the prevailing paradigm of watchful waiting may have to be reconsidered. 
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Conclusions
For the vast majority of asymptomatic patients with severe aortic stenosis, watchful waiting appears to be the most reasonable strategy (Figure 3 ). These patients, especially those with 1 or more high-risk features, require close monitoring, with prompt surgical intervention immediately after symptom onset or with evidence of LV function deterioration.
In selected cases and selected institutions where surgical mortality and morbidity are very low, high-risk patients may benefit from preemptive surgery, especially if delays in scheduling surgery are expected because of long waiting lists. Improvements in transcutaneous valve implant technology in the future, however, may change the thresholds for preemptive intervention. In patients in whom symptomatic status is ambiguous, carefully supervised treadmill testing might uncover serious symptoms justifying preemptive surgery, as currently recommended by guidelines. However, for most asymptomatic patients, for now, "If it ain't broke, don't break it or fix it" appears appropriate.
